Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NFkB pathways improving their therapeutic outcome in experimental colitis.

Research output: Contribution to journalArticle

32 Downloads (Pure)

Abstract

Hypoxia inducible factor and nuclear factor kappa beta pathways have been proposed as therapeutic targets for several inflammatory diseases. Caffeic acid phenethyl ester (CAPE) and piceatannol (PIC), are natural anti-inflammatory compounds however, poor
bioavailability and limited understanding of biomolecular mechanistic limits its clinical use. The aims of this study are to enhance bioavailability and investigate their impact on nuclear p65 and HIF-1α for the first time in experimental colitis.
Dextran sulphate sodium was used to induce colitis in mice and effect of either free CAPE/ PIC or CAPE/PIC loaded albumin nanoparticles treatment was observed on disease development and levels of cellular p65 and HIF-1α.
Our results indicate that albumin nano-encapsulation of CAPE / PIC not only enhances its anti-inflammatory potential but also potentiates its ability to effectively modulate
inflammation related biomolecular pathways. Hence, combining nanotechnology with
natural compounds could result in development of new therapeutic options for IBD.
Original languageEnglish
JournalDrug Delivery and Translational Research
Early online date14 Nov 2018
Publication statusE-pub ahead of print - 14 Nov 2018

Keywords

  • nanoparticles
  • inflammation
  • colitis
  • hypoxia
  • nuclear factor kappa beta
  • albumin

Fingerprint Dive into the research topics of 'Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NFkB pathways improving their therapeutic outcome in experimental colitis.'. Together they form a unique fingerprint.

  • Research Output

    Open Access
    File
  • 5 Downloads (Pure)
    Open Access
    File
  • 20 Citations (Scopus)
    14 Downloads (Pure)

    Cite this